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Sex differences in cancer mechanisms
Joshua B. Rubin1,2*, Joseph S. Lagas1†, Lauren Broestl1†, Jasmin Sponagel1†, Nathan Rockwell1†, Gina Rhee1†,
Sarah F. Rosen3†, Si Chen4†, Robyn S. Klein2,3, Princess Imoukhuede4 and Jingqin Luo5†
Abstract
We now know that cancer is many different diseases, with great variation even within a single histological subtype.
With the current emphasis on developing personalized approaches to cancer treatment, it is astonishing that we
have not yet systematically incorporated the biology of sex differences into our paradigms for laboratory and
clinical cancer research. While some sex differences in cancer arise through the actions of circulating sex hormones,
other sex differences are independent of estrogen, testosterone, or progesterone levels. Instead, these differences
are the result of sexual differentiation, a process that involves genetic and epigenetic mechanisms, in addition to
acute sex hormone actions. Sexual differentiation begins with fertilization and continues beyond menopause. It
affects virtually every body system, resulting in marked sex differences in such areas as growth, lifespan,
metabolism, and immunity, all of which can impact on cancer progression, treatment response, and survival. These
organismal level differences have correlates at the cellular level, and thus, males and females can fundamentally
differ in their protections and vulnerabilities to cancer, from cellular transformation through all stages of
progression, spread, and response to treatment. Our goal in this review is to cover some of the robust sex
differences that exist in core cancer pathways and to make the case for inclusion of sex as a biological variable in
all laboratory and clinical cancer research. We finish with a discussion of lab- and clinic-based experimental design
that should be used when testing whether sex matters and the appropriate statistical models to apply in data
analysis for rigorous evaluations of potential sex effects. It is our goal to facilitate the evaluation of sex differences in
cancer in order to improve outcomes for all patients.
Keywords: Sex differences, Cancer, Epigenetics, Senescence, Immunity, Metabolism, p53, Tumor Suppressor,
Angiogenesis
Overview of sex differences in cancer
Sex differences are evident in tumor incidence and mor-
tality throughout the world, across a wide age range, and
many different cancer types. Mo,st cancers with a clear
sex difference affect males more than females, with inci-
dence rates ranging from 1.26:1 to 4.86:1 (Table 1).
These male predominant cancers include hematological
malignancies, as well as cancers of the bladder, colon,
skin, liver, and brain [1, 2]. Males not only develop can-
cer more often but are also more likely to die from their
disease [3–5]. To date, sex differences have also been
demonstrated in rates and patterns of metastasis, expres-
sion of prognostic biomarkers, and response to different
types of therapies in several different cancer types [6–8].
Despite this overwhelming evidence, sex differences have
not been consistently considered when studying cancer,
designing therapies, or constructing clinical trials. In
part, this is driven by incomplete recognition of the var-
ied mechanisms that contribute to sexual differentiation
and an overemphasis on the role that circulating sex
hormones plays in mediating sex differences in cancer.
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Circulating estrogen, progesterone, and testosterone, un-
doubtedly, contribute to the genesis and progression of some
cancers. Breast and prostate cancer, for example, clearly re-
spond strongly to circulating sex hormones [9–11].
Additionally, estrogen has been shown to be anti-
tumorigenic for liver and colon cancer (which show a male
predominance), and pro-tumorigenic for meningiomas and
thyroid cancer (which show a female predominance). How-
ever, the molecular basis for the sex disparity in most cancers
is still undefined [12–42]. For most cancer types, the magni-
tude of sex differences in incidence and severity do not paral-
lel the age-dependent changes in circulating sex hormone
abundance [36, 43]. Thus, circulating sex hormone actions
cannot account for all sex differences in cancer, and acute
hormone-independent cancer mechanisms remain to be fully
determined.
Sex differences in cancer as well as in normal physi-
ology, arise through sexual differentiation, a process in-
volving genetics and epigenetics, in addition to acute sex
hormone actions. Consequently, males and females differ
in their rates of growth [44], myelination [45], immunity
[46, 47], cardiovascular function [48], systemic metabol-
ism [49], aging, and wound healing [50]. In this light, it
should come as no surprise that sexual differentiation
Table 1 Cancers with a clear sex disparity in age-adjusted incidence rates per 100,000 according to SEER explorer incidence data
Cancer type Male average incidence rates Female average incidence rates Male:female incidence ratio
Oropharynx and tonsil 4.18 0.86 4.86
Larynx 5.2 1.1 4.73
Esophagus 7.34 1.74 4.22
Urinary Bladder 35.24 8.74 4.03
Mesothelioma 1.58 0.4 3.95
Lip 1.02 0.32 3.19
Liver and intrahepatic bile duct 13.58 4.72 2.88
Tongue 5.22 1.92 2.72
Oral cavity and pharynx 17.02 6.38 2.67
Floor of mouth 0.68 0.3 2.27
Kidney and renal pelvis 22.16 10.92 2.03
Myelodysplastic syndromes 6.2 3.26 1.9
Stomach 10 5.36 1.87
Salivary gland 1.7 1.02 1.67
Leukemia 18.06 10.9 1.66
Melanoma of the skin 28.78 17.46 1.65
Myeloma 8.7 5.58 1.56
Non-Hodgkin lymphoma 23.9 16.22 1.47
Gum and other mouth 1.84 1.28 1.44
Soft tissue including heart 4.14 2.92 1.42
Brain and nervous system 7.52 5.36 1.4
Small intestine 2.74 2.06 1.33
Eye and orbit 1.02 0.78 1.31
Colon and rectum 44.28 33.98 1.3
Lung and bronchus 63.08 48.94 1.29
Pancreas 14.66 11.48 1.28
Hodgkin lymphoma 3 2.38 1.26
Anorectal 1.56 2.22 0.7
Gallbladder 0.9 1.5 0.6
Thyroid 8.04 23.26 0.35
Breast 1.24 127.5 0.01
Incidence rates were calculated by averaging age-adjusted incidence rates per 100,000 from the last 5 years (2012–2016). Male:female ratio was calculated by
dividing the male incidence rate by the female incidence rate, both shown in the table. The geometric mean of the male/female incidence ratio is 1.5
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affects cancer incidence, response to treatment, and
survival.
In this review, we will focus on specific cancer core
mechanisms to illustrate how sexual dimorphisms in basic
biological functions influence cancer biology, and might
impact response to treatment. In some instances, we will
focus on brain tumors for the following reasons: The geo-
metric mean value for the sex differences ratio (M/F) in
cancer incidence is approximately 1.5:1 (Table 1). The bias
in glioblastoma (GBM) incidence is approximately 1.6:1
[51]. We expect that if there are adaptations to make in
our science to best incorporate common mechanisms
underlying sex differences in cancer, they will be most eas-
ily identified in a cancer like GBM, that occurs with a
mean sex bias in incidence and for which there are data
that span the scales of oncology research from the cellular
to the patient level [21, 35, 52–59]. We conclude with a
discussion of the rigorous statistical approaches for study-
ing sex effects in the laboratory and the clinic (Table 2).
Epigenetics
Epigenetics and cancer
Over the past two decades, epigenetic dysregulation has
emerged as a critical mechanism of cancer initiation and
adaptation. We now recognize that essentially all cancer
hallmarks that can be acquired through genetic mutation
can similarly be achieved through epigenetic mecha-
nisms. This can involve aberrant activation or silencing
of specific loci, or global remodeling of the epigenetic
landscape. Genes encoding epigenetic readers, writers,
and erasers, as well as histone proteins themselves, are
frequently mutated in human tumors [60–64], drawing a
direct link between epigenetic dysregulation and tumori-
genesis. Cellular differentiation is a process encoded by
progressive layers of epigenetic restriction [65], and dis-
ruption of the normal epigenetic landscape can enable
cancer cells to reactivate developmental programs and
acquire features resembling stem cells [66, 67]. Epigen-
etic mechanisms also contribute to intra-tumor hetero-
geneity and therapeutic resistance [68–70]. Thus,
targeting tumor epigenetics may be a strategy for im-
proving treatment response [68, 71–73]. In this section,
we will review the evidence that the epigenetic landscape
of male and female cells differs, that this is a critical
mechanism by which sexual dimorphism is established,
and that this fundamental divergence in male and female
biology, present in every cell of the body, has important
implications for cancer risk and treatment.
Sex differences in epigenetics
Numerous studies have identified consistent sex differ-
ences in the epigenetic landscape in multiple tissues,
spanning all ages, and across species. The most exten-
sively profiled sexually dimorphic epigenetic mark is
DNA methylation. Sex-specific methylation patterns
have been observed in blood [74–77], placenta [78], liver
[79–82], pancreas [83], muscle [84], heart [81], and brain
[81, 85–89]. Sex differences in histone modifications
have also been described, although thus far only in
mouse brain [90, 91]. Since the majority of mechanistic
studies on epigenetics and sexual differentiation have
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been performed in the brain, this will be our focus here;
however, since sex differences in epigenetics are found
throughout the body, it is likely that many of these
mechanisms will apply to tissues more broadly.
Sexual dimorphism in the brain has been recognized
since the 1950s and is understood to be largely deter-
mined by exposure to gonadal hormones during a crit-
ical window of in utero development. Early studies in
rodents found that an injection of testosterone adminis-
tered in utero, or during the perinatal period, results in
permanent masculinization of adult behavior in females
[92, 93], and evidence that this model also applies to
humans is supported by case studies of disorders of sex
development [94, 95]. The finding that testosterone ex-
posure resulted in a long-lasting and stable patterning of
sexual differentiation led to the hypothesis that epigen-
etic programming may underlie sex differences, and a
number of studies in the past decade have provided
mechanistic evidence for this theory.
Neonatal female rats have higher levels of the DNA
methyltransferase Dnmt3a in the amygdala compared to
males, and treating with testosterone significantly de-
creased this expression [96], indicating it is an important
regulator of DNA methylation. In agreement with this,
neonatal female rats also had higher methylation levels
in the promoter of the estrogen receptor (ER)-α gene,
compared to both males and females masculinized by
gonadal hormone exposure [97]. Genome wide methyla-
tion surveys of the striatum and bed nucleus of the stria
terminalis/preoptic area (BNST/POA), a known sexually
dimorphic brain region, showed that female mice treated
with testosterone on postnatal day 0 had an altered
methylation pattern that resembled that of males, when
they were profiled at postnatal day 60 [85]. In 2015,
Nugent et al. demonstrated that gonadal steroid expos-
ure during development decreased the activity of DNA
methyltransferases (DNMTs) in the POA, lowering DNA
methylation levels in females to levels equivalent to
males. Knocking out Dnmt3A or pharmacologically inhi-
biting Dnmts masculinized sexual behavior in females,
even when treatment was given outside the critical win-
dow [98]. Additionally, treatment with DNMT inhibitors
reverses some anatomical and functional sex differences
in the POA [99]. Together, these studies suggest that
DNA methylation actively suppresses masculinizing
genes in order to maintain brain feminization, and that
this depends on levels of gonadal hormones during de-
velopment. Intriguingly, when embryonic neural stem
cells (eNSCs) were treated with testosterone in vitro, it
resulted in a global decrease in DNA methylation in
both XX and XY cells [100]. A similar result was re-
ported for DNA methylation in liver, in which males
were hypomethylated compared to females, and this was
dependent on testosterone exposure [82]. These studies
indicate that sexual differentiation involves sex-specific
regulation of DNA methylation.
Differences in male and female methylation patterns
may have important implications for cancer develop-
ment. One epigenetic change recognized in many can-
cers, though with some exceptions (notably isocitrate
dehydrogenase (IDH)-mutant gliomas [101]), is a pro-
pensity for global hypomethylation [102, 103]. DNA hy-
pomethylation is associated with increased cancer
malignancy, and mutations in Dnmts are cancer promot-
ing in multiple mouse models. Broad regions of hypome-
thylation (both DNA and histone) are believed to
contribute to dedifferentiation and the cancer stemcell-
like state, and to increase epigenetic plasticity [62]. An-
other scenario in which cells reacquire a stem cell
phenotype is through reprogramming to induced pluri-
potent stem cells (iPSCs), a process that has some paral-
lels to cancer evolution [67]. During reprogramming,
DNA methylation marks associated with cell type-
specific differentiation are erased, and reprogramming
efficiency can be enhanced by the inhibition of DNMTs
[104]. Thus, male- and female-specific methylation pat-
terns could influence the ability of cancer cells to adopt
a stem cell-like phenotype.
Sex differences in histone modifications also underlie
sexual differentiation of the brain. Matsuda et al. found
that there were sex differences in histone acetylation
levels of the ERα and aromatase promoters, two genes
essential for masculinization, during the critical period.
Inhibiting histone deacetylases (HDACs) at postnatal
day 0/1 resulted in decreased male sexual behavior, sug-
gesting that histone deacetylation is required for proper
sexual differentiation [105]. HDAC inhibitors also elimi-
nated anatomical sex differences in the BNST [106].
Treating eNSCs with testosterone in vitro led to a global
increase in histone H3 acetylation in daughter lineages,
supporting the hypothesis that gonadal hormones can
exert stable effects on the genome via histone modifica-
tions [100]. Of note, upregulated genes in both XX and
XY eNSCs treated with testosterone were highly
enriched for pathways involved in nucleosome
organization, nucleosome assembly, and chromatin as-
sembly, suggesting that testosterone-mediated transcrip-
tional changes could drive downstream epigenetic
reorganization [100]. Together, these studies provide
strong evidence that gonadal steroid exposure during
the critical period mediates sexual differentiation of the
brain via epigenetic mechanisms.
Gonadal hormone exposure is not the only mechanism
by which epigenetics can diverge in males and females.
In preimplantation embryos, hundreds to thousands of
genes differ in expression between the sexes [107–110],
despite the fact that gonadal differentiation has yet to
occur. The basis of sexual dimorphism in these early
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embryos is the unique complement of sex chromosomes
in male (XY) and female (XX) cells. One of the most strik-
ing differences in male and female epigenetics is the in-
activation of the additional X-chromosome in female cells.
This inactivation is orchestrated by the long non-coding
RNA (lncRNA) XIST, which mediates chromosome-wide
silencing through histone deacetylation and subsequent
enrichment of repressive chromatin marks [111]. This re-
sults in a dense, highly stable, heterochromatic region
unique to female cells. Removal of these heterochromatic
marks, and reactivation of the X-chromosome, is one of
the steps that takes place during reprogramming to iPSCs
in mouse cells [112], though the status of the inactive X is
more complicated in human iPSCs [113, 114]. As men-
tioned above, reprogramming to iPSCs has some parallels
to cancer dedifferentiation. Intriguingly, generation of
iPSCs from mouse embryonic fibroblasts is more efficient
when using male cells than when using female cells, and it
is speculated that this may be due to an X-chromosome
reactivation barrier [115]. Furthermore, there is evidence
that X inactivation is lost in some female cancers, through
either mitotic errors or epigenetic dysregulation and re-
activation [116, 117]. Whether X-chromosome reactiva-
tion dynamics contribute to female protection in cancer
has not been investigated.
XIST and other lncRNAs of the X inactivation center
(XIC) may have more direct roles in tumor risk as well.
XIST appears to be both tumor-promoting and tumor-
suppressive, depending on cancer type and context
[118]. Surprisingly, two meta-analyses of XIST in cancer
identified no association between XIST and sex/gender,
but did find that high levels were associated with poor
overall survival [119, 120]. Although XIST is not nor-
mally expressed in XY cells, these studies suggest that
aberrant regulation of this lncRNA can occur in both
male and female tumors. FTX, another lncRNA involved
in X inactivation, has been identified as a putative tumor
suppressor in hepatocellular carcinoma (HCC). It is
expressed at higher levels in tumors from female pa-
tients, positively correlates with survival, and inhibits
HCC cell proliferation and invasion [121]. Additional
XIC lncRNAs, such as JPX [122] and TSIX [123] may
also have roles in cancer initiation and progression. Be-
cause expression of lncRNAs involved in X inactivation
differs in normal XX and XY cells, this could contribute
to sex differences in cancer risk. In addition to the
lncRNAs of the XIC, multiple other lncRNAs, located
throughout the genome, have been identified as sex-
biased in expression [110, 124, 125]. Functions of
lncRNAs include modifying chromatin state and regulat-
ing gene expression [126]; thus, differences in even a
small number of lncRNAs could have wide ranging ef-
fects. As with protein-coding genes, lncRNAs can act as
either tumor suppressors or tumor promoters, and are
now recognized to be frequently dysregulated in cancer
[127–131].
LncRNAs also have important roles in regulating im-
printing. In genomic imprinting, a gene is preferentially
expressed from either the maternal or paternal allele
[132]. Since both male and female embryos inherit a full
set of autosomes from their mother and father, the major-
ity of imprinted regions do not differ between the sexes.
However, there is evidence that, at least in brain, the sex
of the offspring can affect imprinting, with some auto-
somal loci imprinted in one sex but not the other [110,
133]. The greatest differences in imprinting emerge from
the X-chromosome. Male embryos inherit only the mater-
nal X, while female embryos inherit both a maternal and
paternal X [132]. Differences in the phenotype of XO girls
who inherit a paternal (Xp) vs. a maternal (Xm) X-
chromosome, suggest that X-chromosome imprinting
does impact development, particularly in the brain [132,
134]. Intriguingly, one study found a trend towards in-
creased brain volume in XmO girls, compared to XpO girls
[134], suggesting potential roles of X imprinted genes on
regulating growth. However, no studies have examined if
cancer rates differ in XmO or XpO women, or if imprinted
X genes contribute to sex differences in cancer risk.
Prior to X-chromosome inactivation (XCI), female em-
bryos are exposed to a double dose of X-chromosome
genes, while male embryos get a single X dose plus a much
smaller number of Y-chromosome genes. However, even
after X-chromosome inactivation, a percentage of genes on
the X (15% in humans [135] and 3% in mouse [136]) escape
inactivation, and are expressed at higher levels in females.
Differences in X and Y gene expression appear to exert
broad downstream effects, resulting in genome-wide tran-
scriptional differences [100, 110, 137]. One mechanism by
which sex chromosomes may exert broad regulatory effects
is through epigenetic regulation. A number of important
epigenetic modifiers are located on the X-chromosome
[138], including lysine demethylases KDM5C and KDM6A
(UTX). Both KDM5C and KDM6A are known to escape X-
chromosome inactivation, are expressed at higher levels in
females, and do not appear to be fully compensated by their
Y-chromosome paralogues KDM5D and UTY [139–141].
KDM6A and KDM5C are two of several putative tumor
suppressors on the X-chromosome proposed to contribute
to decreased cancer risk in females. These genes, along with
ATRX, DDX3X, CNKSR2, and MAGEC3 are more fre-
quently mutated in male tumors [142], presumably because
females have a second copy to compensate for any loss of
function mutations via XCI escape. KDM6A in particular
has been found to contribute to sex differences in bladder
cancer, where it acts as a tumor suppressor in XX individ-
uals [143]. It has also been identified as a tumor suppressor
in B cell lymphoma [144], T cell acute lymphoblastic
leukemia [145], and pancreatic cancer [146]. In addition to
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differences in the expression levels of protein-coding
genes located on the sex chromosomes, lncRNAs
[147] and microRNAs (miRNAs) can also escape X
inactivation and differ in expression between the
sexes. The X-chromosome contains an unusually high
number of miRNAs, 118 compared to an average of
40–50 on the autosomes [148]. These miRNAs are
regulators of a diverse array of processes, many of
which are relevant to cancer [131, 149, 150].
Finally, in addition to both gonadal hormone and sex
chromosome effects, other complex mechanisms may
contribute to sex differences in epigenetics. For example,
the enzymes that catalyze chromatin modifications require
metabolites as both cofactors and substrates [151, 152],
and to add further complexity, some metabolites can act
as inhibitors of epigenetic enzymes; the ketone body d-β-
hydroxybutyrate is an HDAC inhibitor [153], and the
oncometabolite 2-hydroxyglutarate (2-HG) acts as a com-
petitive antagonist to α-KG-dependent demethylases
[154]. As detailed below, metabolism differs fundamentally
in males and females, providing another potential source
for epigenetic sex differences.
Together, these varied mechanisms lead to fundamen-
tal differences in the epigenomes of male and female
cells that likely contribute to sex differences in the cell
intrinsic barrier to malignant transformation (Fig. 1).
Implications for targeting epigenetics
Given the central role of epigenetic dysregulation in
cancer initiation, progression, and therapeutic resist-
ance, it is no surprise that drugs targeting epigenetic
regulators are emerging as promising cancer thera-
peutics [73]. There is already evidence that treating
with DNMT inhibitors can affect sexually dimorphic
epigenetic marks, even when given after sexual differ-
entiation is complete [98], and a recent study showed
that combination treatment with an EZH2 inhibitor
and HDAC inhibitor at sub-therapeutic levels dis-
rupted X-chromosome inactivation in normal human
female fibroblasts [155]. Furthermore, how sex differ-
ences in epigenetics interact with epigenetic dysregu-
lation in cancer is currently not well understood.
Thus, it will be critical to evaluate clinical efficacy
and side effects of epigenetic therapeutics in both
sexes separately.
Metabolism
Metabolism and cancer
Sex differences in metabolism have been extensively re-
ported during development, adulthood, and in certain
diseases, such as obesity and diabetes. Even though
metabolic reprogramming is an essential process in
cancer, sex differences in cancer metabolism have not
Fig. 1 Sex-specific epigenetic programming may contribute to differential barriers to tumorigenesis in males and females. Divergence in male
and female epigenetics begins from the moment of fertilization, driven by differences in sex chromosome gene expression and metabolic
profiles between XX and XY embryos. Throughout development, additional processes, such as X-chromosome inactivation and gonadal steroid
exposure, further differentiate the sexes. The unique epigenetic landscapes of male and female cells may contribute to sex differences in the
barrier to tumorigenesis, as well as to sex differences in tumor heterogeneity and response to treatments—both conventional and
epigenetic targeted
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yet been considered. Cancer cells undergo metabolic re-
programming to optimize their biomass and energy
production, which allows them to proliferate rapidly.
Metabolic reprogramming involves increased uptake of
nutrients, increased catabolic metabolism to produce
ATP, and increased anabolic metabolism to produce
biomass. The latter also requires cancer cells to repro-
gram mitochondrial metabolism, as many anabolic pro-
cesses take place in the mitochondria. Furthermore,
cancer cells must be able to adapt to the unique meta-
bolic stressors that accompany cancerous growth, in-
cluding shortage of nutrients, insufficient oxygen
supply, and an increase in oxidative stress. Metabolic
reprogramming in cancer cells is heavily reviewed else-
where [156, 157]. In this section, we will focus on three
key components of metabolic reprogramming in cancer:
(i) nutrient utilization, (ii) mitochondrial activity, and
(iii) reactive oxygen species (ROS) regulation. We will
review the literature describing sex differences in these
metabolic processes (summarized in Fig. 2) and discuss
how these sex differences might contribute to sex dis-
parities in cancer.
Sex differences in metabolism
Sex differences in metabolism are evident at every stage of
life and at the organismal, tissue, and cellular levels. Across
multiple species, including mice, bovine, birds, and humans,
male embryos grow faster than female embryos and exhibit
concordant differences in nutrient utilization and energy
consumption [158–163]. In humans, pyruvate and glucose
uptake, as well as lactate production, are significantly higher
in male embryos [158], and the presence of male fetuses
has been associated with elevated maternal fasting plasma
glucose [164, 165]. In cows, a high concentration of glucose
selectively blocks development of female embryos during
the morula to blastocyst transition [166–168]. Furthermore,
glucose metabolism is twice as high in male compared with
female bovine embryos [169], and glycolytic genes such as
Hexokinase-1, Phosphofructokinase-1, Pyruvate kinase-1/2,
GAPDH, and Glucose transporter-1 are all more highly
expressed in male bovine embryos [170]. In contrast, female
bovine embryos exhibit higher pentose phosphate pathway
activity [169]. This sex bias is at least partially due to sex
chromosome complement. The pentose phosphate pathway
genes glucose-6-phosphate dehydrogenase (G6PD) and O-
Fig. 2 Sex differences in metabolic pathways may contribute to sex differences in cancer development, progression, and treatment response.
During development and throughout adulthood, males and females utilize nutrients differently. Males favor carbohydrate and amino acid
metabolism, while females favor fatty acid metabolism. Furthermore, female mitochondria produce less ROS despite their higher mitochondrial
activity. These fundamental sex differences in nutrient utilization and mitochondrial activity may contribute to sex differences in metabolic
reprogramming in cancer cells, which is important during cancer development, cancer progression, and response to anti-cancer treatment. This
schematic focuses on metabolic pathways that are known to be sexually dimorphic and important in cancer. Metabolic pathways, metabolites,
and metabolic enzymes shown in blue or pink are known to be higher in males or females respectively
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linked N-acetylglucosamine (GlcNac) transferase (OGT)
are located on the X-chromosome and were found to be
more highly expressed in female mouse and bovine em-
bryos respectively [171, 172]. In human adults, metabolites
of carbohydrate pathways such as glycolysis, gluconeogene-
sis, and pyruvate, and fructose, mannose, and sucrose me-
tabolism are enriched in male serum compared to female
serum [173]. In summary, male embryos exhibit higher glu-
cose uptake and glycolytic activity than female embryos,
while female embryos favor the pentose phosphate path-
way. In adults, carbohydrate metabolites are enriched in
serum of males as compared to females.
Sex differences in amino acid utilization have also
been reported. Increased amino acid intake during the
first week of life was associated with a significant
short-term improvement in weight gain in male, but
not female, low birth weight infants [174, 175]. In hu-
man adults, male serum is enriched for amino acid
metabolites, including branched chain amino acid me-
tabolites, glutamate metabolites, lysine metabolites,
phenylalanine and tyrosine metabolites, cysteine and
methionine metabolites, and tryptophan metabolites
[173, 176]. Furthermore, exercising adult men oxidize
significantly higher levels of the branched-chain
amino acid leucine than exercising women [177].
Additionally, the male rat brain contains higher levels
of glutamate and a higher ratio of glutaminase/glu-
tamine synthetase, suggesting that brains of male rats
utilize more glutamate from glutamine [178]. Even in
moths, adult males oxidize certain amino acids (leu-
cine, phenylalanine, and glycine) at a higher rate than
females [179]. Together, these data show that men
exhibit higher levels of most amino acid metabolites
in their serum, and for those amino acids tested,
males exhibit higher rates of metabolism than fe-
males, across different ages and species. Whether this
is true for all amino acids has yet to be determined.
While the above studies indicate that males exhibit
higher rates of glucose and amino acid utilization, fe-
males appear to favor lipid substrates for energy me-
tabolism. Upon exercise and during fasting, women
utilize more fatty acids while men favor carbohydrate
utilization [180]. Numerous publications have shown
that lipid metabolism is sexually dimorphic in humans
and rodents [181]. Briefly, females exhibit higher rates
of lipid biosynthesis than males [182], and enhanced
fatty acid clearance in muscle tissue compared to
males [183, 184], female rat livers incorporate more
fatty acids into glycerolipids and fatty acid oxidation
products [185], female rodents and humans are more
resistant to free fatty acid-induced insulin resistance
[183, 186], and sex differences in expression and ac-
tivity of lipid metabolism enzymes, such as lipopro-
tein lipase, are well established [187].
As males and females differ in their fundamental nu-
trient utilization for metabolism, it is likely that mecha-
nisms of metabolic reprogramming in cancer differ
between men and women. For example, reprogramming
of amino acid and carbohydrate metabolism may be re-
quired for transformation of male cells, while repro-
gramming of fatty acid metabolism may be required for
transformation of female cells. Support for important
sex differences in cancer metabolism comes from two
publications. In the first, glycolytic gene overexpression
in low-grade glioma was shown to correlate with de-
creased survival in men but not women [188]. In the
second, high visceral fat quantity correlated with de-
creased survival in women with renal cell carcinoma but
not men [189]. Thus, sex differences in metabolic repro-
gramming might contribute to different thresholds for
cellular transformation, cancer progression, and out-
come, and might therefore contribute to the sex dispar-
ity in cancer susceptibility and outcome.
For decades, the primary focus in cancer metabolism
research has been on increased nutrient uptake and
utilization through aerobic glycolysis (Warburg effect).
Today, numerous studies have shown that cancer cells
also exploit the mitochondrial tricarboxylic acid cycle
(TCA cycle) and oxidative phosphorylation [190, 191].
Mitochondria are a primary source of reactive oxygen
species (ROS), and ROS production and consumption
through mitochondrial antioxidant pathways, such as
glutathione oxidation, are required for well-balanced
regulation of ROS levels [192]. Mitochondria exhibit a
strong sex-specific behavior as they are exclusively ma-
ternally inherited. A vast body of literature describes tis-
sue and cell-specific sex differences in mitochondria
morphology, function, and oxidative stress regulation
[193]. Here, we will focus specifically on sex differences
in the brain; however, since sex differences in mitochon-
dria have been reported in tissues throughout the body,
including liver, cerebral arteries, white and brown adi-
pose tissue, pancreas, muscle, and heart, our discussion
likely applies to multiple cancer types.
In rat brain, females exhibit higher mitochondrial pro-
tein content and higher mitochondrial activity (higher
electron transport chain enzyme activity and respiration
rate) [194]. These sex differences gradually increase dur-
ing aging [195]. In concordance with these findings, fe-
male mice exhibit an enhanced respiration rate in brain
tissue compared to age-matched male mice [196, 197].
Additionally, mitochondria isolated from female mouse
brains show higher electron transport chain activity and
ATP production than male mitochondria [198]. In con-
trast, isolated male mitochondria exhibit a higher cal-
cium retention capacity, which can augment ATP
production by altering the activity of calcium-sensitive
mitochondrial matrix enzymes [199]. Furthermore,
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in vitro cultures of rat cortical astrocytes under low oxy-
gen conditions showed greater respiratory capacity in
male, compared to female astrocytes [200]. In human
brains, activity of the mitochondrial enzymes citrate syn-
thase, succinate dehydrogenase, and mitochondrial re-
ductase were significantly higher in females, suggesting a
higher mitochondrial activity in women compared to
men [201]. Sex differences in mitochondrial biogenesis
have also been reported but are inconsistent. In the
mouse brain, mitochondrial biogenesis is greater in fe-
males [197], despite evidence for increased expression of
key regulators of mitochondrial biogenesis in males
[202]. In contrast, female rat brains have lower mito-
chondria content than male brains [194], and this sex
difference increases with age [195].
Sex differences in mitochondrial activity suggest that
ROS accumulation, ROS regulation, and sensitivity to
ROS are also sexually dimorphic, as ROS is generated in
the mitochondria during oxidative phosphorylation. In-
deed, despite their higher respiratory activity, female
mouse brains accumulate significantly lower levels of
ROS compared to their age-matched male counterparts
[196, 197]. This is also true in rats. A study by Borras
et al. showed that female rats exhibit significantly higher
expression of antioxidant enzymes, such as glutathione
peroxidase and superoxide dismutase. Consequently, fe-
male rats exhibit lower levels of ROS, despite their in-
creased respiratory activity, resulting in a better
oxidative balance [203]. These findings were comple-
mented by a study from Guevara et al. who showed that
antioxidant enzyme levels were higher in female mito-
chondria [194]. Oxidative damage accumulates in the
brain throughout aging. However, in rat brains, the aging
effect was less marked in females, which accumulated
less oxidative damage as they aged [195]. In humans,
biomarkers of oxidative stress are lower in healthy young
women than in age-matched men [204]. Together, this
data suggests that female mitochondria exhibit a better
oxidative balance, accumulating less ROS despite their
higher respiratory rate. Thus, female mitochondria ap-
pear to be better optimized than male mitochondria.
ROS can be both pro-tumorigenic and anti-
tumorigenic. Certain oncogenic mutations, such as mu-
tations in the Ras pathway, lead to increased ROS levels.
In turn, ROS levels can stimulate growth factor signaling
pathways, driving tumor development through promo-
tion of proliferation, angiogenesis, invasion, and metasta-
sis [205]. Excessive ROS levels, however, can be
cytotoxic, as they can induce apoptosis, autophagy, and
necroptosis [206]. Since male mitochondria accumulate
more ROS than female mitochondria, male cells may
have a higher risk of carcinogenesis than female cells.
Furthermore, it has been shown that, with age, ROS
levels accumulate more in males than in females [195,
204]. A similar correlation can be found with cancer in-
cidence. With age, cancer incidence rate increases with a
steeper slope in men than in women (see “Senescence”
section). Therefore, sex differences in mitochondrial ac-
tivity and ROS regulation may underlie different thresh-
olds for malignant transformation in men and women
and might therefore contribute to sex differences in can-
cer susceptibility.
Implications for targeting metabolism
In the last decade, metabolic targeting in cancer has
made many advances. However, sex has not been
adequately considered as a biological variable in can-
cer metabolism. Here, we will discuss metabolic treat-
ment approaches that are currently in clinical trials
for cancer and why they might have sex-specific
effects.
Inhibiting the PI3K/mTOR pathway has been shown
to be effective in many cancers, and multiple PI3K/
mTOR inhibitors are currently in clinical trials [207,
208]. The PI3K/mTOR pathway is a major regulator of
metabolism [209]. Sex differences in metabolic pathways
such as glycolysis raise the question of whether the
PI3K/mTOR pathway might be sexually dimorphic, and
therefore, underlie sex differences in metabolic path-
ways. In fact, research done in drosophila and murine
heart tissue showed that the PI3K/mTOR pathway activ-
ity is different in males and females [210, 211], which
suggests that targeting this pathway might result in sex-
specific responses.
Amino acid metabolism and carbohydrate metabol-
ism have also been targeted in cancer. The effect of
the glutaminase inhibitor CB-839 and the effect of a
ketogenic diet (low-carbohydrate diet) are both cur-
rently being evaluated in clinical trials [212, 213].
Most published data indicate that males utilize more
carbohydrate and amino acid substrates for metabol-
ism, while females utilize more fatty acids. Therefore,
targeting amino acid and carbohydrate metabolism
might have sex-specific effects. Targeting mitochon-
dria to induce apoptosis through increased ROS levels
has also been shown to be effective in treating brain
cancer in mice, and the mitochondrial-targeting drug
dichloroacetate (DCA) has been tested in patients
with glioblastoma [214, 215]. Given the large body of
literature demonstrating sex differences in mitochon-
drial activity and ROS accumulation, it is likely that
targeting ROS might have different effects in men
and women with cancer. Since male mitochondria ac-
cumulate more ROS than female mitochondria, male
cancers may more readily exhaust their capacity to
regulate ROS, and consequently, may respond to ROS
elevating treatments more robustly than female
cancers.
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Among the notable recent discoveries in cancer
genome-wide sequencing was the discovery of the isoci-
trate dehydrogenase 1 and 2 (IDH1/2) R132H mutation.
IDH1/2 is an enzyme in the TCA cycle that catalyzes
the conversion of isocitrate to citrate, and its reverse re-
action. Mutant IDH1/2 exhibits loss of normal function
and gain of aberrant function, in which isocitrate is
converted into D-2-hydroxyglutarate (2-HG), an onco-
metabolite that has far-reaching pro-tumorigenic ef-
fects on epigenetic regulation, DNA repair, and redox
state [216, 217]. Due to its importance for mitochon-
drial biomass production, oxidative phosphorylation,
and fatty acid synthesis, disruption of the TCA cycle
through mutant IDH1/2 will most likely result in sex-
specific effects during tumor development, progres-
sion, and treatment response. In concordance, mutant
IDH1/2 inhibitors, which are currently in clinical tri-
als for multiple cancers [218] might exhibit sex-
specific effects. In glioblastoma, a sex-specific effect
of IDH mutations on overall survival has been evalu-
ated in multiple publications [56, 59, 219]; however,
the findings are inconsistent and further study will be
required to define how interaction between IDH1 mu-
tation and patient sex impacts on survival.
p53
p53 in cancer
The tumor suppressor TP53 (p53) is the most fre-
quently mutated gene in cancer, with mutations oc-
curring across almost all cancer types and in
approximately half of all tumors [220, 221]. p53 is
best known as a transcription factor that regulates
target genes in response to DNA damage or onco-
genic stress to induce cell cycle arrest or apoptosis.
In this simplified model, p53 inhibits tumorigenesis
by arresting or eliminating preneoplastic cells [222].
Loss of p53 function through mutation or alterations
in upstream regulators eliminates this barrier, leading
to increased proliferation, genomic instability, and the
accumulation of new mutations that drive tumorigen-
esis. However, p53 actually functions at the center of
a complex network of pathways, and can produce
many phenotypic outcomes depending on the specific
stimulus, tissue or cell type, age, and as described
below, sex. In addition to proliferation and DNA
damage response, p53 plays important roles in metab-
olism, pluripotency, epigenetics, ROS regulation, chro-
matin stability, epithelial to mesenchymal transition
(EMT) and invasion, inflammation, and the tumor
microenvironment [223]. Currently, tumors are most
typically bifurcated into p53-WT and p53-mutant
groups, but this is an oversimplification. Mutations in
p53 can drive many distinct phenotypes depending on
the type of mutation (e.g., missense, truncating,
frameshift), co-mutations in other genes, and tissue
type [223]. Notably, the most common mutations are
missense mutations in the DNA binding domain,
many of which have been ascribed with distinct gain-
of-function abilities that are more oncogenic than
complete p53 deletion [221, 224]. Together, this sup-
ports that p53 function is context dependent and
must be evaluated within each distinct setting to
understand its role in cancer. Here, we will review
current evidence on sex differences in p53 function
and discuss how these sex differences might contrib-
ute to the sex disparity in cancer.
Sex differences in p53
While p53 is best known for its role as a tumor suppres-
sor, it exhibits sex differences in function across many
tissues, throughout normal development and aging. Dur-
ing meiosis, p53 monitors germ cells for DNA damage
in males and induces necrosis to eliminate mutant sper-
matocytes. In female germ cells however, this role is car-
ried out by the p53 family members p63 and p73 [225,
226]. p53 also has differential effects on in utero devel-
opment. p53 null mice appear developmentally normal
but exhibit a sex bias in the ratio of male to female pro-
geny. In the absence of p53, female mice develop neural
tube defects that are embryonic lethal. This was recently
shown to be caused by incomplete X-inactivation and
disruptions in X-gene dosage [227]. p53 directly regu-
lates the long non-coding RNA X-inactivation specific
transcript (Xist), which is a primary effector of X-
inactivation, and the loss of p53 decreases Xist expres-
sion [228].
Sex differences in birth defects in p53 mutant mice
may also be related to a sexually dimorphic role for p53
in epigenetic imprinting. Methylation sequencing re-
vealed that female p53 null offspring with birth defects
displayed a hypermethylation phenotype for insulin-like
growth-factor 2, compared to mice born without birth
defects [229], suggesting a female biased role for p53 in
monitoring epigenetic marks during development. Work
in drosophila also suggests that p53 may be sexually di-
morphic in aging. Overexpression of wild type p53 in
flies increased the lifespan of males, while decreasing the
lifespan of females [230].
An essential function of p53 is the monitoring of DNA
damage and the clearance of pre-neoplastic cells by senes-
cence or apoptosis. A growing body of evidence suggests
that the cells-of-origin for GBM are oligodendrocyte pre-
cursor cells (OPC) that arise in the subventricular zone
(SVZ) before migrating to the cortices [231, 232]. Kim and
Casaccia-Bonnefil found that as mice mature, the number
of neural progenitor cells in the SVZ decreases faster in
males than in females; deletion of p53 eliminated this sex
difference. Co-treatment of SVZ cells in vitro with
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radiation and sex hormones revealed that estrogen, but
not testosterone, reduced p53 expression and apoptosis in
response to DNA damage [233]. This suggests that p53
function in the SVZ is sexually dimorphic during normal
development and in response to exogenously induced
DNA damage and may contribute to the sex differences in
incidence and survival observed in GBM.
Sex differences in p53 function are readily observed in
patients with Li-Fraumeni syndrome (LFS). LFS is a fa-
milial cancer predisposition syndrome associated with
germline mutations in p53 [234, 235]. LFS patients have
a 50% risk of cancer before the age of 30, and an over
90% lifetime risk [236, 237]. The most frequent cancer
types include breast cancer, soft tissue sarcoma, brain/
CNS tumors, bone sarcoma, and adrenocortical carcin-
oma. Even when controlling for the high rate of female
breast cancer, multiple LFS family cohort studies have
concluded that female mutant p53 carriers have an in-
creased risk of developing cancer compared to male car-
riers [236–239]. Importantly, the numbers of mutant
p53 carriers were equivalent between males and females,
suggesting that males and females have differential re-
sponses to the same mutations in p53, leading to greater
risk of cancer development in females. However, Oliver
et al. contradict these findings [240]. They observed that
mutant p53 carriers exhibited a male bias in cancer inci-
dence that matched the male bias in incidence observed
in individuals with sporadic p53 mutations. All five stud-
ies, however, reported a female bias in adrenocortical
carcinoma (ACC) incidence, which is corroborated by
data reported by the International Pediatric Adrenocorti-
cal Tumor Registry [241]. Pediatric ACC is a rare cancer
(0.72/million/year in the USA) and is strongly associated
with mutations in p53 [242]. Because many of these pa-
tients are prepubescent, these data provide further sup-
port that males and females respond differently to p53
mutations in a tissue-specific manner, and that these dif-
ferential responses cannot be explained by the effects of
circulating sex hormones.
The p53 pathway, encompassing p53 and its upstream
regulators, is mutated in approximately 84% of primary
GBM tumors [243]. In primary astrocytes lacking the
tumor suppressor neurofibromin (NF1), p53 loss is suffi-
cient to induce sex differences in transformation, leading
to greater proliferation and clonogenic frequency in
male cells compared to female cells. Furthermore, this
p53 loss contributed to sex differences in in vivo tumori-
genesis. When otherwise isogenic male and female astro-
cytes lacking functional NF1 and p53 were injected into
the brains of both male and female mice, the mice
injected with male cells were more likely to form tu-
mors, regardless of the sex of the host mouse [35]. This
finding was replicated in a second model of GBM, in
which NF1 and p53 were knocked-out in utero by
injecting clustered regularly interspaced short palin-
dromic repeats (CRISPR)/CRISPR-associated protein 9
(Cas9) constructs into the lateral ventricles of E14
mouse embryos, and electroporating to target progenitor
cells in the SVZ. While all mice developed GBM, males
developed tumors and succumbed to their disease faster
than females [21]. Depletion of the tumor suppressors
RB1, CDKN2A (p16), or CDKN1A (p21) in females elim-
inated this difference, suggesting female astrocytes pos-
sess at least partial compensatory mechanisms for cell
cycle regulation in the absence of p53 [21, 35], which
contribute to the greater barrier to tumorigenesis in
these cells.
In addition to the direct effects of p53, some p53 regu-
lators may also contribute to sex differences in cancer.
The E3 ubiquitin-protein mouse double minute 2 homo-
log (Mdm2) is a direct regulator of p53 protein stability
[244]. Under normal conditions, Mdm2 binds and ubi-
quitinates p53 leading to proteasomal degradation [245].
In response to cell stress, p53 is phosphorylated, pre-
venting Mdm2 interaction and subsequent degradation
[246]. In many tumors with WTp53, the p53 pathway is
suppressed through amplification and overexpression of
Mdm2 [247]. MDM2 SNP 309 is a T/G single nucleotide
polymorphism in the promoter of MDM2 that increases
affinity for the transcription factor Sp1, driving increased
expression of Mdm2 mRNA and protein [248]. The T/G
allele drives an estrogen-dependent increase in cancer
risk in females [249]. A recent study by Haupt et al.
identified a network of X-linked genes associated with
p53 function [250]. They found that mutations in p53
regulatory genes on the X-chromosome were expressed
at the mRNA level less frequently in females than in
males with the same mutation. This increased rate of
non-expressed mutations occurred more frequently in
p53 pathway linked-genes than unaffiliated genes, sug-
gesting that females may be able to protect the p53 path-
way through selective inactivation of mutant genes on
the X-chromosome.
Implications for targeting p53
p53 has garnered considerable support over the last two
decades as a candidate target for cancer treatment. Pri-
marily, attempts at targeting p53 have relied on one of
three methods: (1) introduction of exogenous WTp53,
(2) inhibition of negative regulators of p53 such as
Mdm2, or (3) small molecules that can force mutant p53
into a wild type conformation with normalized function
[251, 252]. Each of these methods is based on the obser-
vation that WTp53 is induced in response to oncogenic
stress, so that reactivation of the p53 pathway may slow
or eliminate cancer. Given the growing body of evidence
for sex differences in p53 function, p53 regulators, and
tumor initiation and progression, preclinical and clinical
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studies focused on targeting p53 should be powered to
identify sex differences in treatment response.
Cellular senescence
Senescence and cancer
Cellular senescence is the process of permanent cell
cycle arrest that occurs in response to cellular aging or
DNA instability. Senescence primarily acts as a tumor
suppressor mechanism, by preventing continued prolif-
eration of damaged, potentially tumorigenic cells [253,
254]. Despite cell cycle exit, senescent cells remain meta-
bolically active and release factors known as the
senescence-associated secretory phenotype (SASP) [253–
255]. SASP can have both pro- and anti-tumorigenic ef-
fects on the tissue landscape [254, 256–260]. Anti-
tumorigenic SASP factors can induce senescence in
neighboring cells to safeguard against tumor formation,
or recruit immune cells for clearance of tumor cells and
senescent cells [254, 256, 257, 260, 261]. Pro-
tumorigenic SASP factors can facilitate malignant trans-
formation, promote proliferation, and disrupt tissue
structure, tissue function, and/or immune activity to cre-
ate a tumor promoting environment [255, 259]. Adding
to this complexity, senescent cells express distinct SASP
profiles that depend on multiple variables, including
cell-of-origin, tissue-of-origin, and cause of senescence
[253, 255]. For example, Ras-induced senescent human
fibroblasts secrete greater levels of factors that promote
transformation, compared to senescent fibroblasts in-
duced by replicative exhaustion or irradiation [262]. In
mice, Ras-induced senescent hepatic cells produce SASP
that suppresses hepatocellular tumorigenesis, by increas-
ing cell clearance [263]. In contrast, Pten-loss-induced
senescent prostate cells release cytokines that generate a
pro-tumorigenic environment, characterized by in-
creased immunosuppressive myeloid-derived suppressor
cells (MDSC) and decreased lymphocyte activity [264].
In these ways, senescent cells and SASP play a dynamic
and complex role in cancer development, progression,
and response to treatment. Here, we will review the
current evidence on sex differences in senescence, and
discuss how these differences might contribute to sex
disparities in cancer.
Sex differences in senescence
Worldwide, women live longer than men [265, 266], and
numerous age-associated diseases—including cardiovas-
cular diseases, neurodegenerative disorders, and can-
cer—exhibit sex differences in presentation, response to
treatment, and mortality [267]. Senescent cells and SASP
are important mediators of normal and pathological
aging phenotypes. Baker et al. presented that the elimin-
ation of senescent cells in mouse models attenuates age-
associated changes in multiple tissues. Briefly, senescent
cell clearance was associated with greater muscle fiber
diameter, preserved muscle function, greater fat deposits,
and delayed onset of lordokyphosis and cataracts [268].
In a subsequent study, the group further showed that
the clearance of senescent cells led to improved struc-
ture and function of the kidney and heart, as well as an
increased general healthspan, increased lifespan, and in-
creased tumor latency [269]. Recently, Ruhland et al.
showed that senescent cells increase local inflammation
in both mouse models and human skin, and that SASP-
derived cytokines can promote MDSC infiltration to
generate a tumor-permissive environment [259]. These
studies support that the accumulation of senescent cells
and the release of SASP can have significant impacts on
the tissue landscape and can result in tissue dysfunction,
inflammation, and tumor formation. Accordingly, nu-
merous studies have demonstrated that senescent cells
and SASP are major contributors to multiple age-
associated pathologies, such as neurofibrillary tangles,
atherosclerosis, osteoarthritis, and cancer [254–257,
259–261, 268–274], which also exhibit significant sex
differences in incidence and severity. Given the substan-
tial sex differences in aging and age-associated patholo-
gies, and the evidence that senescence-associated
changes in tissue homeostasis mediate many of these
pathologies, it seems likely that sex differences in senes-
cence could be a contributing factor. However, this has
yet to be investigated directly.
Cancer incidence and prevalence rates rise more
steeply in males than females with increasing age (Fig. 3)
[275]. Whether this is a consequence of sex differences
in cellular senescence is unknown. Cells activate senes-
cence as a protective response to DNA-damaging
stressors, including telomere attrition, oncogene activa-
tion, oxidative stress, and drug/toxin exposure [276–
279]. The induction of senescence depends on: (1) the
magnitude of genotoxic stress and (2) cellular thresholds
for senescence activation; sex may affect both factors.
On average, males have shorter telomere lengths than
age-matched females, and male cells exhibit faster rates
of telomere attrition than female cells [280]. Conse-
quently, male cells may encounter telomere dysfunction
sooner than female cells. Furthermore, male cells are
more prone to oxidative damage (see “Metabolism” sec-
tion) and accumulate more somatic mutations than fe-
male cells [280]. Together, these studies suggest that
males may have a greater risk of exposure to DNA-
destabilizing events than females. Finally, there may be
sexual dimorphism in toxin metabolism, which can re-
sult in sex differences in vulnerability to drug-induced
damage. Males and females express distinct activity
levels of cytochrome-P450 (CYP450) and UDP-
glucuronosyltransferase (UGT) isoforms—two essential
enzymatic families involved in drug metabolism [281,
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282]. However, the significance of these results to under-
standing sex differences in drug metabolism and drug-
induced cellular damage remains to be elucidated.
While males may exhibit greater DNA damage than fe-
males, they may not necessarily activate senescence more
frequently. DNA damage activates DNA-damage response
(DDR) kinases, such as ATM or ATR [253, 283]. When
the damage is determined as irreparable, DDR kinases up-
regulate the p53-p21 and p16INK4a-Rb pathways, resulting
in either senescence or apoptosis [253, 283]. Interestingly,
under some circumstances, damaged cells remain prolifer-
ative despite these protective mechanisms. There may be
sex differences in the degree of activation and conse-
quences of these pathways. Malorni et al. found that male
and female vascular smooth muscle cells (VSMC) exhibit
distinct responses to DNA-damaging stress. After irradi-
ation, male VSMCs more readily underwent apoptosis,
whereas female VSMCs expressed senescence characteris-
tics [284]. While sex hormones partially contribute to this
sex difference in cell fate [285], cell-intrinsic sex differ-
ences are likely involved as well. As described above, there
is evidence for sexual dimorphism in cell cycle regulatory
pathways (see “p53” section). Notably, after loss of NF1
and p53 function, female astrocytes were more likely to
upregulate Rb, p16, and p21—cell cycle regulators in-
volved in senescence—and were less likely to undergo ma-
lignant transformation compared to male astrocytes [21,
35]. DNA damage repair, apoptosis, and senescence, each
serve as barriers to transformation. However, these path-
ways are interconnected, and dysfunction in key regulators
can affect more than one safeguard. For example, loss of
p53 function can compromise both DNA damage repair
and pro-apoptotic pathways [286], and activation of com-
pensatory mechanisms such as senescence becomes ne-
cessary to avoid transformation. Thus, a male resistance
to activating regulators of senescence likely increases their
risk for transformation and may contribute to the ob-
served male risk for cancer (Fig. 3).
After senescence induction, the subsequent clearance
of senescent cells is important to minimize the accumu-
lation of senescent cells in tissue. As detailed above, the
accumulation of senescent cells is associated with mul-
tiple age-related diseases, and the elimination of senes-
cent cells leads to increased healthspan, increased
lifespan, and the mitigation of age-associated phenotypes
and pathologies [254–257, 259–261, 268–274]. A recent
study revealed that in both aged wild type mice (30
months) and progeroid mice, males express significantly
greater levels of p16 and p21 mRNA in the liver, kidney,
and spleen than age-matched females. This sex disparity
was decreased in wild-type mice at the extremes of old
age (35 months): p16 mRNA levels remained signifi-
cantly lower in the liver and spleen of females compared
to males, while p21 mRNA levels in the spleen were sig-
nificantly greater in females than males [287]. These re-
sults suggest that males bear a larger load of senescent
cells than females throughout aging, which may be influ-
encing the increased male risk for various age-related
pathologies, including cancer.
Finally, as mentioned above, senescent cells can also
contribute to tumorigenesis through the release of SASP.
Given the heterogeneous nature of SASP, sex also may
influence the magnitude and/or types of factors released.
Yet no studies have investigated sex effects on SASP or
how sex differences in SASP affect tumor development
or growth.
Implications for targeting senescence
With increasing age, tissue structure and function are
increasingly influenced by the accumulation of senescent
Fig. 3 Sex differences in senescence and SASP may contribute to the increasing sex disparity in cancer incidence with age. a Cancer incidence
increases more steeply in males than in females with age, according to SEER explorer data from 2012–2016266. b Sex differences in cell cycle
regulators, metabolism, and epigenetics can all result in sex differences in senescence activation and SASP. Senescence induction can decrease
the risk of transformation in damaged or aged cells, whereas SASP can have both anti-tumorigenic and pro-tumorigenic consequences on the
aging tissue. In this way, sex differences in senescence and SASP may contribute to the observed age and sex effects on cancer
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cells and the effects of their SASP. This has a significant
effect on disease, including cancer. Furthermore, irradi-
ation and chemotherapy, which are mainstays of anti-
cancer therapy, can activate therapy-induced senescence
(TIS) in cancer cells and neighboring cells. This has
been associated with increased therapy-associated tox-
icity and increased risk for cancer recurrence [288]. For
these reasons, there has been growing interest in adju-
vant therapies that target senescence to improve treat-
ment response and reduce risk of relapse. These include
senescence-inducing drugs, SASP-inhibiting agents,
senolytics, senostatics, and synergistic therapies [289,
290]. The development of senescence-targeting drugs is
still relatively young, and most agents are undergoing
preclinical testing on animal and xenograft models with
mixed results. However, there have been recent advances
in the field. Particularly, the FDA recently approved pal-
bociclib, a CDK4/6 inhibitor and senescence-inducing
agent, for use in ER+/HER2-advanced breast cancer pa-
tients [291]. There are also multiple clinical trials study-
ing the efficacy of the combination therapy of navitoclax,
a senolytic agent, and chemotherapy against various can-
cer types. Unfortunately, completed studies show no
change in the objective response rate [292]. A common
obstacle in the development of senescence-targeted
treatments is the lack of a clear understanding of the
senescence response and SASP. Further investigation
into the mechanisms involved will be integral to formu-
lating more effective treatment strategies, and it is likely
that sex-adapted approaches to targeting senescence will
be required for the greatest success.
Immunity
Immune system in cancer
The immune system plays a significant role in cancer de-
velopment and progression [293]. This has led to the in-
clusion of “evading immune destruction” as a hallmark
of cancer [294]. There are numerous mechanisms by
which tumors avoid immune responses, such as suppres-
sion of regulatory T cells [295], down-modulation of
antigen processing [296], induction of immune suppres-
sive mediators [297], and promotion of tolerance and
immune deviation [298, 299]. As adult females generally
mount stronger innate and adaptive immune responses
than males [47, 300], sex differences in the immune sys-
tem likely contribute to the sexual disparity in incidence
and mortality associated with certain cancers. Here, we
will discuss sex differences in the immune system, and
how these differences can lead to sex differences in can-
cer incidence, mortality, and treatment efficacy.
Sex differences in the immune system
In the innate immune system, females have antigen-
presenting cells (APCs) that are more efficient at
presenting peptides than males [301]. As cancer cells
modulate antigen-presentation to evade immune de-
struction, sex differences in APCs and their downstream
effector cells can have significant impact on anti-tumor
immunity and immunotherapy responses. For example,
B7-homolog 1 (B7-H1), a co-signaling molecule
expressed abundantly on APCs, which contributes to
tumor immune evasion and induces T regulatory cell
(Treg) function [302], has been found to be modulated
in an estrogen-dependent manner. As a result of re-
duced Treg function allowing for antitumor immunity,
female B7-H1 knock-out mice are more resistant to syn-
geneic B16 melanoma tumor formation than males
[303]. Females also have been shown to have higher
numbers and greater phagocytic activity of macrophages
and neutrophils than males [304, 305]. Hepatocellular
carcinoma (HCC), the most common liver cancer, is 3
to 5 times more likely to develop in males than females
[306]. In a mouse model of HCC using a chemical car-
cinogen, diethylnitrosamine (DEN), it was found that IL-
6 production by Kupffer cells (KC), resident liver macro-
phages, was higher in males than females. IL-6 has been
found to be in large concentrations in the tumor micro-
environment and is deregulated in cancers [307]. Estro-
gen reduced circulating IL-6 levels in DEN-treated mice,
providing a potential explanation for the reduced liver
cancer risk in females [27]. Additionally, there exists a
large sex disparity in lung cancer oncogenesis following
epithelial Stat3 deletion in mice with induced mutant K-
ras. In males, the absence of epithelial STAT3 promotes
lung tumorigenesis via enhanced IL-6 [308] signaling
and neutrophilic inflammation, which is inhibited in fe-
males by estrogen signaling. These studies suggest that
estrogen may inhibit inflammatory cytokine secretion by
macrophages and neutrophils, reducing cancer risk in fe-
males. Conversely, women have a higher incidence of
non-small cell lung cancer (NSCLC) [309], but have
been shown to have better prognoses than males [29]. It
has been suggested that sex differences in NSCLC are
due to immune differences, as female NSCLC patients
exhibit significantly different immune gene set enrich-
ment compared to males [310].
Within the adaptive immune system several key
immune-related genes, such as FOXP3 and CD40L, are
located on the X-chromosome. Also, numerous genes
expressed in T cells carry the estrogen response element
in their promoters, leading to stronger inflammatory and
cytotoxic T cell responses in females. These include
IFN-γ, IFI6, CX3CL1, CX3CL2, IL-1, IL-5, and IL-16
[311]. The two estrogen receptor subtypes (ERα and
ERβ) are expressed on T cells and B cells, suggesting a
direct regulatory role of estrogens on these cell types
[312]. In humans, CD4+ T cells from females produce
higher levels of IFN-γ and proliferate more than male
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CD4+ T cells. However, male CD4+ T cells have in-
creased IL-17A production compared to females [313].
IL-17A has been shown to have the ability to both in-
crease tumor progression by activating angiogenesis and
immunosuppressive activities, and inhibit tumor pro-
gression, through recruitment of immune cells into tu-
mors and stimulation of effector CD8+ T cells [314]. Sex
differences in T cells of animal models are more pro-
nounced, with CD4+ T cells from females being associ-
ated with increased production of IFN-γ and increased
responsiveness to IL-12 through STAT-4 activation
[312, 313]. These data suggest that the more robust T
cell response in females may be beneficial for antitumor
immunity. Thus, immunological sex differences in the
innate and adaptive immune system, due to both sex
hormones and X-linked genes, could contribute to the
etiology of sex-related cancer disparities.
Implications for immunotherapy
Despite known sex differences in immune responses
and functions (Fig. 4), the effect of sex on cancer im-
munotherapy was not investigated until recently. Suc-
cessful immunotherapy could enhance the ability of the
immune system to mount an effective neo-antigen-
specific antitumor response, or stimulate the immune
system more generally to mount a vigorous immune re-
sponse [315]. At least three sites of immune action can
be targeted for therapeutic intervention: promoting
antigen presentation by dendritic cells (DCs), promot-
ing the production of protective T cell responses, and
overcoming immunosuppression in the tumor micro-
environment. Estrogens are important regulators of the
development and function of DC precursors and DC
cell subsets, including plasmacytoid DCs (PDCs), which
are a high priority immunotherapy target [316, 317].
Furthermore, females exhibit higher CD4+ T cell
counts and higher CD4/CD8 ratios, whereas males have
higher numbers of CD8+ and Tregs [47, 318]. Immuno-
therapies rely on effective antitumor immunity in the
tumor microenvironment, which can be achieved by
recruiting tumor-infiltrating leukocytes to the site
[315]. As leukocyte populations are dramatically af-
fected by sex, antitumor immune responses may display
sexual dimorphisms that impact on the efficacy of can-
cer immunotherapies [319].
Anti-tumor immunotherapy treatments can be
antigen-specific, as in monoclonal antibodies, vaccines,
and CAR-T cells. There are also antigen-agnostic ther-
apies, such as oncolytic virus therapy and immune
checkpoint inhibitors (ICIs), which act as inhibitors of
programmed cell death receptor 1 (PD-1) and cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4). ICIs have
been shown to significantly prolong the overall survival
of patients with advanced tumors, by restoring effica-
cious antitumor immunity [320]. However, these therap-
ies have disproportionately increased efficacy in male
compared to female patients [3, 321]. It has also been
shown that tumor mutational burden, rather than PD-L1
expression, has a much better predictive power for fe-
male response to ICI compared to male response, in
lung cancer patients [322]. Furthermore, women experi-
ence more immune-related adverse effects compared
with men during treatment with anti-PD-1 drugs [323].
The molecular basis for sex differences in response to
ICI treatments remains to be fully explored. To date,
preclinical studies have demonstrated that the PD-1 lig-
and (PD-L1)/PD-1 pathway can be regulated by sex ste-
roids [316, 324]. Furthermore, PD-L1 expression has
Fig. 4 Sex differences in immune cells affecting cancer development. Effects of gonadal hormones and sex chromosomes on cells of the innate
and adaptive immune system affecting cancer development. Pink shaded region refers to female differences, and blue shaded region refers to
male differences. See text for details
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been shown to be modulated by several X-linked micro-
RNAs (miRNAs), such as miR-221, miR-222, miR106b,
miR-20b, and miR-513 [325]. The X-linked miR424 tar-
gets both PD-L1 and CD80, resulting in regulatory con-
trol of both the PD-L1/PD-1 and CD80/CTLA-4
pathways [326]. Since mechanisms affecting X-linked
genes, such as silencing escape and X-inactivation skew-
ing, could also influence X-linked miRNAs, it is possible
that these miRNAs contribute to sex differences in the
immune system [327].
As the PD-L1/PD-1 and CD80/CTLA-4 pathways are
important targets for ICIs, it is crucial to consider their
sexual dimorphism during immunotherapy. For example,
as estrogen increases intracellular PD-1 expression
[324], female patients may need a higher dose of an ICI
to achieve equal immunotherapy efficacy as males. Like-
wise, as males and females have different numbers and
phenotypes of T cell subsets, it may be beneficial to tar-
get a specific cell population in each sex to mount ef-
fective antitumor immunity. Accordingly, it is critical to
consider sex differences in immune functioning and re-
sponses when designing cancer preclinical and clinical
studies.
Angiogenesis
Angiogenesis and cancer
Angiogenesis, the formation of new blood vessels from
pre-existing ones, is a hallmark of cancer [294, 328].
Blood vessels are primarily composed of endothelial cells
(ECs), which interconnect through tight junctions to
form the endothelial lining. Notably, in healthy adults,
the vasculature remains quiescent under normal condi-
tions, except for ECs in the female reproductive tract
during menstrual cycles and pregnancy [329]. Within
the hypoxic tumor microenvironment, abundant pro-
angiogenic growth factors are released, including vascu-
lar endothelial growth factors (VEGFs), fibroblast growth
factors (FGFs), and platelet-derived growth factors
(PDGFs) [330–332]. These pro-angiogenic factors bind
to pro-angiogenic receptors on ECs, such as VEGF
receptor-2 (VEGFR2) [333–336] and integrins [337,
338], and activate downstream signaling pathways like
PI3K/Akt [339], leading to endothelial nitric oxide syn-
thase (eNOS) activation [340]. Activated ECs secrete
proteases such as matrix metalloproteases (MMPs) to
dissolve local basement membrane and extracellular
matrix (ECM), allowing ECs to migrate towards the an-
giogenic stimuli [341]. The signaling events further in-
crease EC proliferation, survival, and differentiation,
allowing new capillaries to form and elongate [342, 343].
During angiogenesis, bone marrow-derived endothelial
progenitor cells (EPCs) are recruited to the endothelial
lining of new blood vessels through vasculogenesis [344].
Other key cell types involved in this angiogenic process
include macrophages, pericytes, and fibroblasts [345–
348]. In healthy tissue, the process of angiogenesis is
tightly regulated by the balance of pro-angiogenic and
anti-angiogenic factors, whereas in cancer, this balance
is altered to sustain tumor growth, development, and
metastasis [342, 349]. Here, we will review current evi-
dence on sex differences in angiogenesis, and discuss
how these differences may contribute to sex differences
in cancer.
Sex differences in angiogenesis
Evidence for sex differences in tumor angiogenesis is
limited, with one recent study showing more lym-
phangiogensis and angiogenesis in lung adenocarcin-
oma from young female patients than from men
[350]. However, several sex differences in EC pheno-
types and genotypes, EPC mobilization, circulating an-
giogenic factors, perivascular tissues, and effects of
sex hormones on angiogenesis have been described,
thus providing a template for studying sex differences
in tumor angiogenesis (Fig. 5).
Female and male ECs present intrinsically different an-
giogenic phenotypes, and increasing evidence indicates
that angiogenesis in males and females may be
dependent on different mechanisms. Human umbilical
endothelial cells (HUVECs), a macrovascular cell model
commonly used for endothelial studies in vitro, when
isolated from female newborns, show higher migration
ability compared to cells isolated from males [351]. This
finding aligns with an ex vivo study that shows faster mi-
gration in female macrovascular ECs from rat skeletal
muscle compared to male samples [352]. The sexual di-
morphism in EC migration ability may be a consequence
of female ECs expressing more cell adhesion molecules,
including Integrin αvβ3 [352], which promote EC migra-
tion through mediating cell-matrix and cell-cell associ-
ation [337]. Female ECs express higher eNOS and
VEGFR2, which may further modulate EC proliferation
and migration [351, 353, 354]. Conversely, HUVECs
from male newborns are more autophagic than female
cells [351]. As EC autophagy has emerged as a critical
mechanism facilitating tumor angiogenesis [355], this
sex difference in autophagy may contribute to sex differ-
ences in tumor angiogenesis, tumor growth, and re-
sponse to anticancer therapy. Moreover, one study
found that female EC sprouting relies on eNOS-
mediated migration, while male capillary outgrowth is
independent of eNOS but requires cell proliferation
[354], suggesting that mechanisms in angiogenesis may
be different for male and female ECs. Together, these
findings suggest female ECs facilitate angiogenesis
mainly through integrin, VEGFR, and eNOS-mediated
migration, while male ECs may be less migratory but
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can still promote angiogenesis through proliferation and
other underexplored mechanisms such as autophagy.
In addition to the intrinsic sex differences in ECs, ef-
fects of sex hormones, especially estrogen, on angiogen-
esis have been extensively examined [352, 356, 357].
Studies have identified the expression of ER, progester-
one receptor (PR), and androgen receptor (AR) on both
ECs and EPCs [351, 358–361]. Androgen was reported
to promote proliferation, migration, and angiogenesis in
male ECs but not female ECs, both in vitro and in vivo,
by the regulation of key angiogenesis-related genes, in-
cluding HIF-1α and SDF-1α [362]. Estrogen, specifically
estradiol (E2), causes rapid eNOS production and in-
creases EC proliferation and migration via ERα and ERβ;
although, multiple studies reported that ERα may play a
more significant role [357, 359, 361]. E2 can induce bone
marrow-derived EPC mobilization via ER binding,
followed by PI3K pathway activation, eNOS induction,
and FGF-2 production [357]. This E2-mediated EPC
mobilization may explain the higher number of EPC
(CD34+ VEGFR2+) observed in pre-menopausal women,
whereas no significant difference was found between
post-menopausal women and age-matched men [363].
E2 has also been found to modestly correlate with
hematopoietic progenitor cell counts in women [364].
Interestingly, similar E2-mediated EPC mobilization was
also observed in male mice with hindlimb ischemia [356,
365]; additionally, a higher number of EPCs were ob-
served in men with cardiovascular diseases than age-
matched women [357], suggesting hormonal regulated
angiogenesis may be confounded by cardiovascular dis-
eases. In addition to ECs and EPCs, emerging evidences
show that estrogen has an effect on a wide variety of
cells in the perivascular environment, including tumor
cells, smooth muscle cells, fibroblasts, pericytes, macro-
phages, and adipose tissue, which can indirectly upregu-
late angiogenesis by induction of pro-angiogenic factors
such as VEGF [366–369]. Together, these estrogen-
mediated pro-angiogenic effects align with preclinical
and clinical evidence, where a positive correlation be-
tween ER expression, angiogenic activity, tumor size,
and invasiveness was observed for several cancer types,
including breast cancer and lung cancer [350, 370–372].
Sex differences are also evident in the abundance of
circulating angiogenic factors. One study of platelet-rich
plasma found that pro-angiogenic factors, including
Fig. 5 Sex differences in endothelial cells (ECs), endothelial progenitor cells (EPCs), circulating angiogenic factors, and sex hormones contribute to
sex differences in tumor angiogenesis. Female and male ECs express different levels of growth factor receptors, integrins, and cell adhesion
molecules, which lead to different abilities to migrate and proliferate, and sex-dependent angiogenic mechanisms. Bone marrow-derived EPCs are
more abundant in females, which could be a result of sex hormone regulation. Further, estrogen and androgen facilitate angiogenesis through
different mechanisms. Finally, females and males have different amounts of circulating pro-angiogenic and anti-angiogenic factors, which may
further contribute to the sex differences in tumor angiogenesis
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epidermal growth factor (EGF), insulin growth factor-1
(IGF-1), PDGF-BB, and VEGF, were significantly higher
in women [373]. Conversely, another study of platelet-
rich plasma found that PDGF-BB was higher in men and
found no sex differences in IGF-1 levels [374]. The same
study also found that interleukin-1 beta (IL-1β) and sev-
eral angiogenic growth factors, including tumor necrosis
factor-alpha (TNF-α), basic fibroblast growth factor
(bFGF), and transforming growth factor-beta 1(TGF-β1)
were higher in males [374]. Further studies do not show
a strict pro-angiogenic correlation in females versus
males in serum; anti-angiogenic factor angiopoietin-2
and pro-angiogenic factor IL-3 were higher in females,
while anti-angiogenic thrombospondin (TSP) and sev-
eral pro-angiogenic endothelial adhesion molecules
(E-selectin, VCAM-1) were higher in males [375]. The
same study also showed that MMP-7 and MMP-9
were more abundant in female serum, whereas MMP-
3 was higher in male serum [375]. These results indicate
a need for meta-analysis to determine if correlations exist
between pro- vs. anti-angiogenic factors and sex. Further,
these findings suggest a need to uncover why certain
growth factors, cytokines, and proteases have sexually di-
morphic expression, and whether these sexual dimor-
phisms translate to differential angiogenic signaling and
function.
Implications for targeting tumor angiogenesis
Since 2004, 14 anti-angiogenic drugs have been ap-
proved by the Food and Drug Administration [376].
Primary methods for targeting tumor angiogenesis
have relied on antibody inhibitors that block angio-
genic growth factors such as VEGF, PDGF, and their
signaling pathways [377, 378]. There is already evi-
dence showing sex-dependent response to bevacizu-
mab, a monoclonal antibody that blocks VEGF [379–
381]. As increasing evidence demonstrates sex differ-
ences in survival outcomes of cancer and responses
to therapies [59, 382], preclinical and clinical studies
focused on inhibiting angiogenesis should be powered
to identify sex differences in treatment response. Fur-
thermore, systematic analysis is necessary in discover-
ing sex-specific molecular targets for anti-angiogenic
therapies.
Systems biology offers a promising approach to dis-
cover sex-specific molecular targets, and thereby im-
prove anti-angiogenic therapy. Previously, angiogenic
receptors on ECs and other perivascular cells have been
extensively characterized [336, 353, 383–386] and com-
putationally modeled [387–390]. Computational models,
based on mass-action kinetics of the signaling axis, have
characterized VEGF–VEGFR binding in both healthy
and diseased tissue [391, 392], VEGF spatial distribution
in skeletal muscle [393–395], angiogenic sprouting in
skeletal muscle [396, 397], and VEGF gradients in per-
ipheral artery disease (PAD) [398]. A recent computa-
tional model, which incorporated ex vivo VEGFR
concentrations from breast cancer xenografts, predicted
that tumors having “high” concentrations of plasma
membrane VEGFR1 could be resistant to anti-VEGF
drugs (angiogenesis inhibitors) [384, 399]. This systems
biology approach, which combines computational mod-
eling and quantitative profiling of the biological system,
can similarly predict how sex differences in angiogenic
factors and cell receptors can result in differential anti-
angiogenic drug response.
Statistical considerations
In order to optimally detect sex differences in cancer
mechanisms like those described above, investigators
in the laboratory and the clinic must move beyond
simple comparisons of males versus females using t
tests to evaluate the significance of their differences.
Popular analysis strategies for assessing sex differ-
ences in cancer are either incorrect or insufficient.
Sex differences cannot be inferred from a two-way
ANOVA with sex and treatment only; the analysis
must include treatment and sex interaction. It is sim-
ple and appealing to conduct simple two sample t
tests to compare treatment within each sex, but this
practice is inefficient and insufficient, since no formal
inference can be made on the sex difference. Even if
an interaction term is incorporated into an ANOVA
model, how to derive the contrast to appropriately es-
timate sex differences is not trivial for most re-
searchers. Appropriate study design, statistical
modeling, and tests are required for detecting that
interaction. Here, we will briefly consider the neces-
sary components to perform rigorous evaluations of
sex effects in cancer.
While completely randomized treatment assign-
ments among a cohort of mice of both sexes is a
valid approach to study an interaction effect, devi-
ation from balanced treatment assignments to the two
sexes will critically reduce the efficiency of detecting
interactions. More effective detection of interactions
between treatment and sex, as well as their main
effects, can be achieved with a balanced two by two
(2 × 2) factorial design. Proper implementation of the
factorial design requires randomization and blinding,
fundamentals of clinical trial design that are often
missing in animal experiments.
To illustrate the essential statistical aspects, we
evaluate a treatment efficacy outcome, which can be
quantitative, binary, or time to event, of two treat-
ments (vehicle vs. treatment) that may differ by sex
(female vs. male). Statistical interaction can be visual-
ized by line plots as shown in Fig. 6. Clinical efficacy
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outcome (assume higher values correspond to better
efficacy here) is plotted against treatment, for female
and male separately. Two parallel lines indicate the
absence of statistical interaction, while two non-paral-
lel lines indicate some interaction exists between
treatment and sex. Quantitative interaction (synonym-
ously, non-crossover interaction) exists when treat-
ments benefit both sexes, but with varying magnitude
(here females show greater improvement with treat-
ment than male). Qualitative interaction (synonym-
ously cross-over interaction) [400] is present if
treatment effects by sex trend in opposing directions
(here, treatment is beneficial to female but harmful to
male).
In retrospective studies, descriptive statistics can first
be generated to summarize an efficacy outcome by com-
binations of treatment and sex, and sex-attributable ef-
fects can be visualized using appropriate plots (Fig. 6). A
linear model (or factorial Analysis of Variance (ANOVA)
in a balanced design) for a quantitative outcome, a logis-
tic model for a binary outcome, or a Cox proportional
hazard model for a survival outcome, can be applied to
model the main effects and the interaction effect. The
point estimates of treatment efficacy difference between
sexes can be estimated, accompanied with 95% confi-
dence interval, though the analysis results are usually
regarded as exploratory and are used to generate new
hypotheses to prospectively test the existence of a spe-
cific type of interaction.
In prospectively designed study on the interaction, we
usually conduct two-sided hypothesis testing where an
alternative hypothesis (H1) of unequal treatment efficacy
between sexes is tested against a null hypothesis (H0) of
equal treatment effect. In other words, we test on a non-
zero difference in treatment efficacy against a zero dif-
ference between male and female. Let δF and δM denote
the efficacy difference of treatment versus vehicle in fe-
male and male, respectively. The two-sided hypothesis
testing can be mathematically written as,
H0 : δ F−δM ¼ 0 versusH1 : δM−δM≠ 0:
Depending on how treatment efficacy is measured,
the efficacy difference δ can denote the arithmetic dif-
ference in the mean efficacy between treatment and
vehicle for a quantitatively measured efficacy outcome
(Fig. 6), or the odds ratio in logarithm scale for a
binary outcome (namely, δF and δM representing log
odds for response in female and male, respectively),
or the relative risk (hazard ratio) in logarithm scale
for a survival outcome (with δF and δM representing
log hazard for survival in female and male, respect-
ively). For a continuous treatment efficacy outcome Y,
the sex attributable treatment efficacy difference can
be written as,
δ F−δM ¼ ðY f emaleTreatment−Y f emaleVehicleÞ−ðYmaleTreatment−YmaleVehicleÞ
with Y denoting the mean treatment efficacy under a
treatment for a specific sex, as labeled. The treatment ef-
ficacy difference can be estimated and tested against
zero by fitting a linear model with the main effects of
treatment, sex, and the interaction.
Fig. 6 Visualizing statistical interaction. Clinical efficacy outcome of vehicle and treatment is indicated on the y-axis. a In the presence of the
same treatment effect within sex, the sex-specific efficacy lines are parallel, indicating no statistical interaction. In the presence of sex-attributable
differences in treatment effect, the two lines will no longer be parallel. In b, a quantitative interaction exists between treatment and sex, where
treatment improves clinical efficacy in both sexes, but the magnitude of improvement in male is not as great as in female. In c, a qualitative
interaction exists between treatment and sex, where the treatment benefits female but is detrimental to male, resulting in treatment effects in
opposing directions
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For two-sided hypothesis testing on a qualitative inter-
action, we specifically test on the presence of opposing
directions against the same direction, namely,
H0 : δ F > 0 and δM > 0ð Þ or δ F < 0 and δM < 0ð Þ
versus H1 : δ F > 0 and δM < 0ð Þ or δ F < 0 and δM > 0ð Þ
A chi-square heterogeneity test on treatment effect
can be used to test quantitative interaction, where the
point estimates and standard errors for treatment differ-
ence (e.g., hazard ratio or odds ratio) in each sex are es-
timated and a test statistic is subsequently constructed
using Equation (5) and (6) in Gail and Simon [400]. A
Gail-Simon likelihood ratio test (GS LR test) can be used
to perform specific testing on the presence of a qualita-
tive interaction (using Equation (3a) and (3b) in Gail and
Simon [400]) for both a two-sided and a one-sided test.
A range test [401] has also been proposed for testing
qualitative interaction, which has been reported to have
similar power as the GS LR test [400] when only two
subgroups (e.g., male and female) are involved.
Sample size needs to be pre-calculated for a prospect-
ive study to ensure sufficient power detecting the inter-
action. For a quantitative outcome, using the sample size
equation for normal distribution [402], the total sample
size of the study needed to detect the interaction with a
type I error rate of α and type II error rate of β (i.e.,
power = 1-β) can be approximated by,
n ¼ 16
2 Z1−β þ Z1−α=2
 
δ F−δMð Þ2
;
with Z indicating normal quantiles and σ2 for the variance of
the outcome, and thus n/4 for each of the four groups by the
combination of treatment and sex. For detecting an inter-
action between two binary factors in logistic regression for a
binary outcome, an online app can be utilized (https://www.
dartmouth.edu/~eugened/power-samplesize.php), by specify-
ing the frequencies of outcome, treatment and sex, and the
main effect odds ratios of treatment and sex for the binary
outcome, as well as the interaction odds ratio [403]. For de-
tecting an interaction between two correlated binary factors
in the Cox proportional hazard model for a survival out-
come, Equation (6) in Schmoor, et al. [404] can be employed
to calculate the sample size; this has been implemented in
the R package “powerSurvEpi” (http://CRAN.R-project.org/
package=powerSurvEpi), involving the four groups’ preva-
lence and the hazard ratio of the interaction term. For testing
the qualitative interaction using either the GS LR test or the
range test, no closed form equation can be used to derive
the sample size, and thus simulations have to be used to jus-
tify sample size.
Above, we have provided a very brief overview of the
statistically relevant issues, focusing on the interaction
between two binary factors (treatment and sex). Other
methods and test statistics have been proposed in the lit-
erature for additional situations, such as treatment inter-
acting with a continuous factor, or more complex,
multiple factor interactions.
Perspectives and significance
Sexual differentiation typically results in two normal and
distinct body morphologies and supporting physiologies.
This is required for the sex-specific reproductive roles of
males and females. The resultant sexual dimorphisms
encompass genetic, epigenetic, and metabolic mecha-
nisms at the cellular level, as well as systemic effects on
every body system. Consequently, normal growth and
aging differ in males and females, as does risk and sever-
ity of multiple diseases. Cancer is among those diseases
with significant sex differences in risk, treatment re-
sponse, and outcome. It is imperative that we incorpor-
ate the potential for sex differences to significantly
impact on the cell and systems biology of cancer. Fur-
ther, we must accept that these sex differences in cancer
biology will affect how males and females respond to
therapy, be it standard cytotoxic chemo- and radiation-
therapies, immunotherapy, metabolic therapies, or tar-
geted agents. It is essential that our laboratory and clin-
ical research be appropriately powered and analyzed to
detect sex effects. Similarly, as the implications of gender
identity on health and disease become better defined,
these should also be included in paradigms for oncology
research and treatment. This is the only way that we can
hope to follow through on the promise of precision
medicine, to provide the very best care for each and
every individual affected by cancer.
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